文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-FDG PET/CT 可视化非恢复期 ICU 患者持续炎症与隐匿感染:VIPER 研究方案

Visualizing Persistent Inflammation and Occult Infections in Nonrecovering ICU Patients with [18F]FDG PET/CT: VIPER Study Protocol.
PubMed 文献 · J Nucl Med · 2026-09-10

VIPER 为前瞻性、双中心、国际头对头诊断比较观察性队列研究,拟入组 ICU 住院≥7 天、存在器官衰竭且炎症指标持续升高患者,在入 ICU 第 8–15 天同期行 18F-FDG PET/CT 与增强 CT,主要终点为两种影像发现发生率分类,并记录成像后 48 小时内治疗改变及循环生物标志物与影像关系。

要点

  • 针对 ICU 持续危重症患者,同期比较 18F-FDG PET/CT 与增强 CT 对感染/炎症灶的检出。
  • 主要终点按 PET/CT 四分类统计发现发生率,采用交叉交换盲法标准化评估。
  • 记录成像后 48 小时内治疗改变,并分析循环生物标志物与影像发现关系。

核心结论

  • 该方案旨在探索 18F-FDG PET/CT 相较增强 CT 在持续危重症患者中检测感染和炎症灶的价值,并评估影像对治疗决策的影响。

研究设计与样本

  • 前瞻性、双中心、国际头对头诊断比较观察性队列研究,入组 ICU 住院至少 7 天、存在器官衰竭且炎症参数持续升高的患者。
  • 入组后在 ICU 第 8 至 15 天同期进行 18F-FDG PET/CT 与增强 CT,并通过两机构间交叉交换扫描实现盲法标准化评估。

关键数值与推荐

  • 主要结局为两种影像方式的发现发生率,结果分类为 PET 阳性/CT 阳性、PET 阴性/CT 阳性、PET 阳性/CT 阴性或 PET 阴性/CT 阴性。
  • 成像后 48 小时内的治疗改变将被记录,成像前由主管医生填写预期治疗计划及已知或疑似病灶问卷。
  • 入组当天和成像当天采集血样用于循环生物标志物分析。

临床怎么用

  • 扫描结果直接临床可用并整合入决策,以评估 18F-FDG PET/CT 作为 ICU 患者管理附加诊断工具的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of [18F]FDG PET/CT for detection of infectious and inflammatory foci in patients admitted to the intensive care unit (ICU) has gained interest as previous retrospective studies have shown promising results. [18F]FDG PET/CT in these studies was predominantly performed in patients with prolonged organ failure. These patients often acquire an immune dysregulated state, resulting in infectious complications impairing organ recovery. Early detection of infectious or inflammatory foci in this population may improve outcomes and reduce health care costs. We aim to explore the value of [18F]FDG PET in comparison to contrast-enhanced CT (ceCT) for the detection of infectious and inflammatory foci in patients with persistent critical illness. In addition, we will assess the influence of imaging findings on therapy changes after the scans and the relation between circulating biomarkers and [18F]FDG PET/CT findings. Methods: This study protocol describes a prospective, dual-center, international, head-to-head diagnostic comparison observational cohort study. Patients admitted to the ICU for at least 7 d with organ failure and persistently increased inflammatory parameters are eligible for inclusion. After inclusion, [18F]FDG PET/CT and ceCT will be performed simultaneously between day 8 and day 15 of ICU admission. For the primary endpoint, masked and standardized assessment of the scans will be ensured by exchanging the scans cross-over between both institutions. Primary outcome will be the incidence of findings for both imaging modalities, categorizing the results as PET-positive/CT-positive, PET-negative/CT-positive, PET-positive/CT-negative, or PET-negative/CT-negative. Direct clinical availability of the scans will allow for integration into decision-making. Therapy changes within 48 h after imaging will be recorded. Additionally, a questionnaire on the expected therapy plan and known or suspected foci is completed by the attending physician before the imaging procedure to better assess the impact of imaging on decision-making. Blood samples are taken on the day of inclusion and imaging. Conclusion: This first large prospective study will explore the application of [18F]FDG PET/CT compared with ceCT to image infectious and inflammatory foci in persistent critically ill patients. This study may help define the role of [18F]FDG PET/CT imaging in the ICU environment, supporting clinicians with an additional diagnostic tool for patient management.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Stee CP, van Leer B, Pinto Pereira J, et al. Visualizing Persistent Inflammation and Occult Infections in Nonrecovering ICU Patients with [18F]FDG PET/CT: VIPER Study Protocol. J Nucl Med. 2026. PMID: 42722437. doi:10.2967/jnumed.126.272736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。